Új-Zéland - angol - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml - solution for injection - 20 mg/ml - active: morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml - solution for injection - 50 mg/5ml - active: morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: citric acid; water for injections; sodium methyl hydroxybenzoate; disodium edetate; glycerol; sodium citrate dihydrate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; citric acid; sodium methyl hydroxybenzoate; glycerol; water for injections; disodium edetate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 2 mg/ml - oral liquid, solution - excipient ingredients: sodium methyl hydroxybenzoate; glycerol; sodium citrate dihydrate; water for injections; disodium edetate; citric acid - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: disodium edetate; glycerol; water for injections; sodium methyl hydroxybenzoate; citric acid; sodium citrate dihydrate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 50 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - movapo is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with movapo should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 20 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - movapo is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with movapo should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

Írország - angol - HPRA (Health Products Regulatory Authority)

pharmaceuticals sales & development sweden ab (pharmswed) - apomorphine hydrochloride hemihydrate - solution for infusion - 5 milligram(s)/millilitre - dopamine agonists; apomorphine

Írország - angol - HPRA (Health Products Regulatory Authority)

evolan pharma ab - apomorphine hydrochloride hemihydrate - solution for infusion - 5 milligram(s)/millilitre - dopamine agonists; apomorphine